Axovant's IPO: Harbinger Of A Biotech Bubble?
This article was originally published in Start Up
In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.
You may also be interested in...
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.